Total: $187.08M | ||||
Company (Symbol)# (M) |
Type Of Financing |
Number Of Shares, Units Or Warrants |
Amount Raised (M) |
Investors; Placement Agents; Details (Date)@ |
| ||||
| ||||
AspenBio Inc. |
Private |
N/A |
$1.25 |
The units were sold at $17,500 each and each consists of 20,000 unregistered shares and 20,000 warrants exercisable for three years at $1.50 per share (7/21) |
| ||||
Calypte |
Private |
3.7S and |
$1.5 |
The shares were sold for $0.40 each and the five-year warrants are exercisable at $0.50 per share, the same terms as the first part of the financing in June that brought in $9.3M (7/13) |
| ||||
Cellegy |
Private |
3.02S and |
$10.3 |
Shares in the private placement, primarily with institutional investors, were sold at $3.42 each; the warrants are exercisable at $4.62 per share (7/27) |
| ||||
ConjuChem |
Private |
N/A |
C$25 |
The 7.07% notes were sold to Baker Brothers Investments and can be converted into common stock at C$5 per share; the deal also includes 0.35 warrants per underlying common share exercisable at C$6.25 per share (7/20) |
| ||||
Corautus |
Convertible |
N/A |
$5 |
Corautus closed on a $5M loan from Boston Scientific Corp. under a July 2003 agreement; the loan could increase to up to $15M under the milestone-driven deal (7/26) |
| ||||
Corautus |
Private |
0.943S and |
$4.93 |
Shares in the first tranche of a financing were sold at $5.22 each; the second tranche would include the same number of shares on the same terms; each tranche includes 235,869 warrants exercisable at a 20% premium at the time of the deal (7/7) |
| ||||
Evotec OAI |
Private |
2.5S |
€7.5 |
The shares were sold at €3 each; Sal. Oppenheim was global coordinator for the financing (7/14) |
| ||||
Generex |
Private |
2.46S and |
$3 |
The warrants in the deal are exercisable at $1.68 per share; the four participating investors have an option to purchase the same number of shares and warrants on the same terms (7/13) |
| ||||
GlycoGenesys |
Private |
10S and |
$5 |
Institutions purchased the shares at $0.50 each and the warrants are exercisable at $1 per share (7/12) |
| ||||
Idenix |
Private |
5.4S |
$75.6 |
The shares were sold to Novartis Pharma AG in conjunction with Idenix's IPO; the stock was sold at the IPO price of $14 per share; Novartis retained its 57% stake in Idenix through the purchase (7/21) |
| ||||
Miraculins |
Private |
1U |
C$0.4 |
Each unit consists of one share and one-half of a warrant; each full warrant is convertible for six months into a common share at C$1.55; McFarlane Gordon Inc. and Bieber Securities Inc. were agents for the offering, and received 36,000 warrants exercisable at C$1.25 as part of the deal (7/27) |
| ||||
MultiCell |
Private sale |
ND |
$2 |
Ascendiant Securities LLC was placement agent in the deal, which entailed the sale of convertible preferred stock and warrants (7/13) |
| ||||
Norwood |
Options |
ND |
$10.1 |
Norwood Abbey raised $10.1M from the exercise of options that expired June 30 (7/1) |
| ||||
Novavax Inc. |
Private |
N/A and |
$40 |
In conjunction with its reacquisition of Estrasorb from King Pharmaceuticals Inc., Novavax sold 4.75% senior convertible notes to institutional investors along with 952,381 common shares at $5.25 per share; the notes are convertible into stock at $6.15 per share (7/19) |
| ||||
| ||||
Notes: | ||||
This chart does not include real estate or manufacturing plant financings. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
@ Dates refer to the date of the press release. | ||||
Currencies conversions are based on exchange rates at the time of the deal. | ||||
N/A = Not applicable; ND = Not disclosed. | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange. |